103 related articles for article (PubMed ID: 9650367)
21. In vitro activity of new quinoxalin 1,4-dioxide derivatives against strains of Mycobacterium tuberculosis and other mycobacteria.
Zanetti S; Sechi LA; Molicotti P; Cannas S; Bua A; Deriu A; Carta A; Paglietti G
Int J Antimicrob Agents; 2005 Feb; 25(2):179-81. PubMed ID: 15664491
[No Abstract] [Full Text] [Related]
22. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling.
Gumbo T; Louie A; Deziel MR; Parsons LM; Salfinger M; Drusano GL
J Infect Dis; 2004 Nov; 190(9):1642-51. PubMed ID: 15478070
[TBL] [Abstract][Full Text] [Related]
23. Novel N-aryl- and N-heteryl phenazine-1-carboxamides as potential agents for the treatment of infections sustained by drug-resistant and multidrug-resistant Mycobacterium tuberculosis.
De Logu A; Palchykovska LH; Kostina VH; Sanna A; Meleddu R; Chisu L; Alexeeva IV; Shved AD
Int J Antimicrob Agents; 2009 Mar; 33(3):223-9. PubMed ID: 19070992
[TBL] [Abstract][Full Text] [Related]
24. Preparation and in-vitro evaluation of 4-benzylsulfanylpyridine-2-carbohydrazides as potential antituberculosis agents.
Herzigová P; Klimesová V; Palát K; Kaustová J; Dahse HM; Möllmann U
Arch Pharm (Weinheim); 2009 Jul; 342(7):394-404. PubMed ID: 19536781
[TBL] [Abstract][Full Text] [Related]
25. Synthesis of novel substituted pyrazolyl-2-toluidinomethanethione and pyrazolyl-2-methoxyanilinomethanethione as potential antitubercular agents.
Ali MA; Yar MS
Acta Pol Pharm; 2007; 64(2):139-46. PubMed ID: 17665863
[TBL] [Abstract][Full Text] [Related]
26. [Comparison of multiple drug-resistance between Mycobacterium avium complex and Mycobacterium fortuitum and Mycobacterium chelonae].
Tsukamura M
Kekkaku; 1988 Aug; 63(8):563-8. PubMed ID: 3184587
[No Abstract] [Full Text] [Related]
27. In vitro and in vivo activities of acylated derivatives of isoniazid against mycobacterium tuberculosis.
Hearn MJ; Cynamon MH
Drug Des Discov; 2003; 18(4):103-8. PubMed ID: 15553921
[TBL] [Abstract][Full Text] [Related]
28. Exclusive mutations related to isoniazid and ethionamide resistance among Mycobacterium tuberculosis isolates from Korea.
Lee H; Cho SN; Bang HE; Lee JH; Bai GH; Kim SJ; Kim JD
Int J Tuberc Lung Dis; 2000 May; 4(5):441-7. PubMed ID: 10815738
[TBL] [Abstract][Full Text] [Related]
29. Antituberculosis agents. VI. Activity of a new ciprofloxacin derivative against Mycobacterium avium and some drug-resistant strains of Mycobacterium tuberculosis.
Foroumadi A; Soltani F; Moshafi MH
Boll Chim Farm; 2002; 141(5):394-6. PubMed ID: 12481384
[TBL] [Abstract][Full Text] [Related]
30. Substituted benzyl-pyrimidines targeting thymidine monophosphate kinase of Mycobacterium tuberculosis: synthesis and in vitro anti-mycobacterial activity.
Gasse C; Douguet D; Huteau V; Marchal G; Munier-Lehmann H; Pochet S
Bioorg Med Chem; 2008 Jun; 16(11):6075-85. PubMed ID: 18467107
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and antitubercular activity of novel 4-substituted imidazolyl-2,6-dimethyl-N3,N5-bisaryl-1,4-dihydropyridine-3,5-dicarboxamides.
Fassihi A; Azadpour Z; Delbari N; Saghaie L; Memarian HR; Sabet R; Alborzi A; Miri R; Pourabbas B; Mardaneh J; Mousavi P; Moeinifard B; Sadeghi-Aliabadi H
Eur J Med Chem; 2009 Aug; 44(8):3253-8. PubMed ID: 19371979
[TBL] [Abstract][Full Text] [Related]
32. Diaryloxy methano phenanthrenes: a new class of antituberculosis agents.
Panda G; Shagufta ; Mishra JK; Chaturvedi V; Srivastava AK; Srivastava R; Srivastava BS
Bioorg Med Chem; 2004 Oct; 12(20):5269-76. PubMed ID: 15388155
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and in-vitro antimycobacterial activity of amino-5-[(substituted) phenyl]-3-(4-hydroxy-3-methylphenyl)-4,5-dihydro-1H-1-pyrazolylmethanethione.
Ali MA; Yar MS; Siddiqui AA; Husain A; Abdullah M
Acta Pol Pharm; 2007; 64(5):435-9. PubMed ID: 18540164
[TBL] [Abstract][Full Text] [Related]
34. Structure-activity relationships of macrolides against Mycobacterium tuberculosis.
Zhu ZJ; Krasnykh O; Pan D; Petukhova V; Yu G; Liu Y; Liu H; Hong S; Wang Y; Wan B; Liang W; Franzblau SG
Tuberculosis (Edinb); 2008 Aug; 88 Suppl 1():S49-63. PubMed ID: 18762153
[TBL] [Abstract][Full Text] [Related]
35. Discovery of novel phenoxyacetic acid derivatives as antimycobacterial agents.
Ali MA; Shaharyar M
Bioorg Med Chem; 2007 Mar; 15(5):1896-902. PubMed ID: 17251028
[TBL] [Abstract][Full Text] [Related]
36. Moxifloxacin lethality against Mycobacterium tuberculosis in the presence and absence of chloramphenicol.
Malik M; Drlica K
Antimicrob Agents Chemother; 2006 Aug; 50(8):2842-4. PubMed ID: 16870782
[TBL] [Abstract][Full Text] [Related]
37. Highly active potential antituberculotics: 3-(4-alkylphenyl)-4-thioxo-2H-1,3-benzoxazine-2(3H)-ones and 3-(4-alkylphenyl)-2H-1,3-benzoxazine-2,4(3H)-dihiones substituted in ring-B by halogen.
Waisser K; Matyk J; Kunes J; Dolezal R; Kaustová J; Dahse HM
Arch Pharm (Weinheim); 2008 Dec; 341(12):800-3. PubMed ID: 19006090
[TBL] [Abstract][Full Text] [Related]
38. QSAR-driven design, synthesis and discovery of potent chalcone derivatives with antitubercular activity.
Gomes MN; Braga RC; Grzelak EM; Neves BJ; Muratov E; Ma R; Klein LL; Cho S; Oliveira GR; Franzblau SG; Andrade CH
Eur J Med Chem; 2017 Sep; 137():126-138. PubMed ID: 28582669
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and in vitro anti Mycobacterium tuberculosis activity of a series of phthalimide derivatives.
Santos JL; Yamasaki PR; Chin CM; Takashi CH; Pavan FR; Leite CQ
Bioorg Med Chem; 2009 Jun; 17(11):3795-9. PubMed ID: 19427791
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of Mycobacteria Growth Indicator Tube (MGIT) for drug susceptibility testing of Mycobacterium tuberculosis.
Palomino JC; Traore H; Fissette K; Portaels F
Int J Tuberc Lung Dis; 1999 Apr; 3(4):344-8. PubMed ID: 10206506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
